Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 5/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17995994 | 0.92 | MAOA (0.41) | ABL1KCNH2SCN9ASCN1ASCN4A | |
| SCHEMBL21294275 | 0.89 | ALDH1A1 (0.46) | ABL1KCNH2SCN9ASCN1ASCN4A | |
| SCHEMBL30574511 | 0.89 | ALDH1A1 (0.46) | ABL1KCNH2SCN9ASCN1ASCN4A | |
| SCHEMBL21308359 | 0.88 | SCN9A (0.38) | KCNH2SCN9AMEN1NPC1CYP1A2 | |
| SCHEMBL18031762 | 0.88 | SMN1; SMN2 (0.43) | SCN9AMEN1NPC1CYP1A2CYP2C9 | |
| SCHEMBL17995993 | 0.83 | KDM1A (0.40) | KCNH2MEN1NPC1CYP1A2CYP2C9 | |
| SCHEMBL18033877 | 0.82 | CYP2C9 (0.40) | ABL1SCN5AMEN1NPC1CYP1A2 | |
| SCHEMBL18033876 | 0.82 | CYP2C9 (0.40) | KCNH2SCN9ASCN1ASCN4ASCN5A | |
| SCHEMBL21308314 | 0.81 | TSHR (0.44) | SCN9AMEN1NPC1CYP1A2CYP2C9 | |
| SCHEMBL21308230 | 0.81 | KCNH2 (0.38) | KCNH2SCN9AMEN1NPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244423-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. (US) | 2016-08-25 | — | — | US | claimed |
| EP-3059232-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | Artax Biopharma Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| US-20250346586-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12319675-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240199592-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2024-06-20 | — | — | US | disclosed |
| CN-117304157-A | Chromene derivatives as inhibitors of TCR-NCK interactions | 阿塔克斯生物制药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-112189009-B | Chromene derivatives as inhibitors of TCR-NCK interactions | 阿塔克斯生物制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220081429-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| US-10696663-B2 | Chromene derivatives as inhibitors of TCR-NCK interaction | ARTAX BIOPHARMA INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2019-08-29 | — | — | US | disclosed |
| US-10131647-B2 | Chromene derivatives substituted by alkoxide as inhibitors of the TCR-Nck interaction | Artex Biopharma Inc. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20160244423-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244423-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3059232-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | Artax Biopharma Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-3059232-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | Artax Biopharma Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015056085-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319675-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | ABL1 799/4885KCNH2 1483/4885SCN9A 1667/4885 |
| US-20240199592-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | ABL1 799/4885KCNH2 1483/4885SCN9A 1667/4885 |
| US-10131647-B2 | Chromene derivatives substituted by alkoxide as inhibitors of the TCR-Nck interaction | NFATC1, NCKAP1, NCK1 | ABL1 1387/4885KCNH2 1373/4885SCN9A 1968/4885 |
| US-20220081429-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | ABL1 799/4885KCNH2 1483/4885SCN9A 1667/4885 |
| US-10696663-B2 | Chromene derivatives as inhibitors of TCR-NCK interaction | NCK1, NCKAP1, NCKAP1L | ABL1 799/4885KCNH2 1483/4885SCN9A 1667/4885 |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | ABL1 799/4885KCNH2 1483/4885SCN9A 1667/4885 |
| US-20160244423-A1 | CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION | NFATC1, NCKAP1, NCK1 | ABL1 1387/4885KCNH2 1373/4885SCN9A 1968/4885 |
| US-20250346586-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | ABL1 799/4885KCNH2 1483/4885SCN9A 1667/4885 |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | ABL1 799/4885KCNH2 1483/4885SCN9A 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.